Cancer Research UK enters new oncology partnership
November 7, 2016Sales and Marketing Cancer Research UK, TYG Oncology, oncology
Cancer Research UK (CRUK) and its commercial arm, Cancer Research Technology (CRT), haven entered into an agreement with TYG Oncology …
Nestle backs allergy biotech Aimmune to the tune of $145 million
November 7, 2016Sales and Marketing Aimmune, allergy therapeutics, nestle
Nestle Health Science has invested $145 million in return for a 15% stake in Aimmune Therapeutics. Aimmune pursues food-allergy therapies …
Merck KGaA invests €250 million in production in China
November 4, 2016Manufacturing and Production China, Merck KGaA, Nantong, manufacturing
Merck KGaA inaugurated their Nantong pharmaceutical plant on 4 November. At the same time, Merck also announced that it plans …
Top Ten articles in the pharma industry this week
November 4, 2016Medical Communications November, news, pharmaceutical, top 10, top ten, top ten stories
This week has seen pharmaceutical companies release their third quarter profits, good news for some whilst others have attempted to …
Sanofi, Lilly & Novo accused of pricing collusion
November 4, 2016Manufacturing and Production, Medical Communications, Sales and Marketing
Bernie Sanders has continued his assault on pharma pricing after calling out Eli Lilly earlier this week by implicating Lilly, …
Lonza grows manufacturing capability by opening further site
November 4, 2016Medical Communications Lonza, drug product services, manufacturing
Lonza, a Swiss multinational chemical and biotechnology company, has opened a new manufacturing facility in Basel, where their headquarters is …
AstraZeneca’s post-heart attack drug gets NICE recommendation
November 4, 2016Medical Communications, Sales and Marketing AstraZeneca, Brillique, NICE, heart attack
AstraZeneca’s Brillique (ticagrelor) has received final recommendation from the National Institute of Health and Care Excellence (NICE) as a prevention …
Blood cancer sufferers to receive early access to BMS’ Opdivo
November 3, 2016Medical Communications Bristol-Myers Squibb, lyphoma, opdivo
Bristol-Myers Squibb has announced that their immunotherapy drug, Opdivo (nivolumab), will be made available to patients in the UK through …
Clinical trials and their patients: The rising costs and how to stem the loss
November 3, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing clinical trials
The pharmaceutical industry has a big problem and it’s one that keeps getting worse every year – how to stop …
NICE approves first new drug for breast cancer in a decade
November 3, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
NICE has approved Eisai’s Halaven (eribulin) for routine treatment of sufferers of locally advanced or metastatic breast cancer that has …
Lily increases diabetes drug by 700% over 20 years
November 3, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bernie Sanders, Eli Lily, Humalog, diabetes
It has come to light that, over a 20 year period, Eli Lily has increased the price of its diabetes …
MSD’s Alzheimer’s study could break new ground for treatment
November 3, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, MSD, clinical trials
MSD, known as Merck in North America, has published results of a Phase I trial of verubecestat. The drug is …
FDA issues warning letter after Chinese firm impedes investigation
November 2, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing China, FDA
The US Food and Drugs Administration (FDA) has issued a Chinese firm with a warning letter after claims it intentionally …
Gilead quietly drops drugs from line up alongide Q3 results
November 2, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abzena, Gilead, research and development
Gilead Sciences followed Pfizer in discreetly dropping a drug alongside its third quarter profit reports. The drug in question, for …
Multi Packaging Solutions wins ‘Packaging Company of the Year’
November 2, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Multi Packaging Solutions (“MPS”)(NYSE: MPSX), a global market leader in healthcare, spirits, confectionery and media packaging, has been voted the …
Avacta joins major US cancer centre for CAR-T immunotherapy development
November 2, 2016Research and Development Avacta, Memorial Sloan Kettering Cancer Center
Biotherapeutic and research reagent developer Avacta has announced it will collaborate with New York’s Memorial Sloan Kettering Cancer Center (MSK, …
Nimbus Therapeutics receives $200 million payment from Gilead
November 2, 2016Research and Development Gilead Sciences, Nimbus Therapeutics, nash
Nimbus Therapeutics only signed a deal with Gilead Sciences back in April of this year and yet have already received …
Celgene partners with IBM for new pharmacovigilance platform
November 2, 2016Research and Development, Sales and Marketing Celgene, Watson, ibm
IBM is set to join forces with Celgene to develop a new drug safety evaluation platform, it has emerged. Running …
Valeant looking at selling core asset to manage debt
November 2, 2016Research and Development Takeda Pharmaceutical, Valeant pharmaceutical, salix
Valeant is rumoured to be looking into selling its Salix drugs business to Takeda Pharmaceutical, with figures floated of a …
Pfizer surprises industry by ending development of projected blockbuster
November 1, 2016Research and Development Pfizer, cholesterol, clinical trials
Pfizer announced the news that it would no longer be developing an experimental cholesterol lowering drug. The drug had been …
Latest content
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
